ImmuPharma appoints Bachem to manufacture key ingredient for diabetes drug

ImmuPharma flags Murcia research into P140 as potential brain cancer treatment

ImmuPharma focused on securing P140 licensing deal in 2026

ImmuPharma launches regulatory push for Kapiglucagon diabetes drug

ImmuPharma: P140 partnering discussions continue; overwhelming backing for investment round

ImmuPharma shares surge 20% as P140 partnering talks advance

ImmuPharma advances P140 partnering talks as patent progress and new study data strengthen programme

ImmuPharma raises up to £7.5m to accelerate diabetes drug development

ImmuPharma draws interest from major pharma groups for P140 partnership

ImmuPharma rallies as partnership talks progress and end-of-year deal target reaffirmed

ImmuPharma is advancing partnership talks, says cash runway has extended

ImmuPharma appoints veteran fund manager Ketan Patel as independent director

ImmuPharma lights up AIM on a dull week for small-caps

Small cap weekly spotlight: pharma stocks see key progress

ImmuPharma soars 141% on new autoimmune patent filing

ImmuPharma files new patent application for autoimmune therapy

ImmuPharma deepens talks with potential partners following progress on autoimmune platform

ImmuPharma in talks with global partners after scientific progress on autoimmune platform

ImmuPharma up 19% after 'stunning' mechanism of action results

ImmuPharma CEO hails 'stunning results' from mechanism of action study of lead asset

ImmuPharma's P140 platform and oversubscribed fundraise - ICYMI

ImmuPharma hails oversubscribed £2.9m investment round

Immupharma says no reason for rocketing share price outside research advance

ImmPharma shares rocket on autoimmune breakthrough

ImmuPharma looking forward to industry talks in San Francisco next week

ImmuPharma interims highlight progress of lead asset

ImmuPharma chief hails year of 'significant scientific progress'

ImmuPharma outlines new approach for lead asset aimed at significantly extending patent life

Incathera shares up 70% on Marionnaud; ImmuPharma jumps 25%